Agi Hamburger, Ph.D.
Chief Operating Officer
Agi Hamburger, Ph.D., is the Chief Operating Officer at A2 Bio, overseeing all aspects of Technical Operations (Process Development, Manufacturing and Supply Chain), Quality, Business Operations (Facilities, EH&S, IT and Office Management), and Translational Science. She also leads an Adaptive Innovation team bridging strategic advancements across the organization. As COO, she is responsible for driving the company’s strategic priorities, ensuring the focus on moving innovative science forward and fostering a culture of teamwork and collaboration. She brings a passion and enthusiasm for building organizations.
Agi joined A2 Bio in February 2018 as one of the company’s first employees. Before stepping into the COO role, she served as Vice President of Discovery Research where she played a key role in establishing a world-class cell therapy discovery organization. Her leadership was instrumental in advancing innovative cell therapies, leveraging high-quality, rigorous science to overcome barriers of immunotherapy.
Prior to A2 Bio, Agi spent 12 years at Amgen where she held numerous positions in the Therapeutic Discovery organization. During this time, Agi made significant contributions to both small and large molecule programs across multiple therapeutic areas, including oncology, neuroscience and cardiometabolic disease, resulting in multiple drug candidates that progressed into clinical development.
Agi received her bachelor’s degree from Purdue University and her Ph.D. from the Massachusetts Institute of Technology prior to conducting a postdoctoral fellowship at the California Institute of Technology.